keyword
MENU ▼
Read by QxMD icon Read
search

Heart failure biomarkers

keyword
https://www.readbyqxmd.com/read/27910296/the-year-since-the-guidelines-a-concise-update-on-recent-advances-in-pulmonary-hypertension
#1
Abhishek Mishra, Maninder Singh, Edo Kaluski
Since the updated pulmonary hypertension (PH) guidelines published in 2015, two major landmark trials have provided additional insight regarding therapeutic algorithms of PH. In this review, we concisely summarized the key findings of peer‑reviewed studies published in the last one year in the field of PH. These studies have enhanced our therapeutic abilities by introducing a new potent agent, selexipag, and by demonstrating the advantage of upfront combination therapy (endothelin receptor antagonist and phosphodiesterase‑5 inhibitor) versus single agent therapy in group 1 PH...
February 2017: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/27908348/nt-probnp-the-gold-standard-biomarker-in-heart-failure
#2
EDITORIAL
Paul M McKie, John C Burnett
No abstract text is available yet for this article.
December 6, 2016: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/27900885/selecting-heart-failure-patients-for-metabolic-interventions
#3
Harmen G Booij, Anne M Koning, Harry van Goor, Rudolf A de Boer, B Daan Westenbrink
Introduction Heart failure (HF) has become the cardiovascular epidemic of the century and now imposes an immense burden on health care systems. While our understanding of the pathophysiology of HF has increased dramatically, the translation of knowledge into clinical practice has been disappointing. Metabolic dysfunction in HF has been studied for eight decades, but these efforts have not resulted in effective therapies. This paucity in clinical translation probably results from the variable contribution of metabolic dysfunction to the underlying heart disease...
November 30, 2016: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/27900617/new-and-evolving-concepts-regarding-the-prognosis-and-treatment-of-cardiac-amyloidosis
#4
REVIEW
Stefano Perlini, Roberta Mussinelli, Francesco Salinaro
Systemic amyloidoses are rare and proteiform diseases, caused by extracellular accumulation of insoluble misfolded fibrillar proteins. Prognosis is dictated by cardiac involvement, which is especially frequent in light chain (AL) and in transthyretin variants (ATTR, both mutated, (ATTRm), and wild-type, (ATTRwt)). Recently, ATTRwt has emerged as a potentially relevant cause of a heart failure with preserved ejection fraction (HFpEF). Cardiac amyloidosis is an archetypal example of restrictive cardiomyopathy, with signs and symptoms of global heart failure and diastolic dysfunction...
November 29, 2016: Current Heart Failure Reports
https://www.readbyqxmd.com/read/27896982/predictive-modeling-of-hospital-readmission-rates-using-electronic-medical-record-wide-machine-learning-a-case-study-using-mount-sinai-heart-failure-cohort
#5
Khader Shameer, Kipp W Johnson, Alexandre Yahi, Riccardo Miotto, L I Li, Doran Ricks, Jebakumar Jebakaran, Patricia Kovatch, Partho P Sengupta, Sengupta Gelijns, Alan Moskovitz, Bruce Darrow, David L David, Andrew Kasarskis, Nicholas P Tatonetti, Sean Pinney, Joel T Dudley
Reduction of preventable hospital readmissions that result from chronic or acute conditions like stroke, heart failure, myocardial infarction and pneumonia remains a significant challenge for improving the outcomes and decreasing the cost of healthcare delivery in the United States. Patient readmission rates are relatively high for conditions like heart failure (HF) despite the implementation of high-quality healthcare delivery operation guidelines created by regulatory authorities. Multiple predictive models are currently available to evaluate potential 30-day readmission rates of patients...
2016: Pacific Symposium on Biocomputing
https://www.readbyqxmd.com/read/27889567/prognostic-value-of-plasma-apelin-concentrations-at-admission-in-patients-with-st-segment-elevation-acute-myocardial-infarction
#6
Jordi Sans-Roselló, Gregori Casals, Xavier Rosselló, Bernardino González de la Presa, Montserrat Vila, Albert Duran-Cambra, Manuel Morales-Ruiz, Andreu Ferrero-Gregori, Wladimiro Jiménez, Alessandro Sionis
BACKGROUND: The use of plasma biomarkers is relevant for the prognosis of ST-segment elevation myocardial infarction (STEMI) patients. Apelin, an adipocytokine, plays a pivotal role in the pathophysiology of both ischemia/reperfusion injury and its potential subsequent heart failure. We evaluated apelin concentrations at admission as a biomarker to assess risk of 6-month mortality. METHODS: Consecutive patients with STEMI were recruited from January 2012 to January 2013 (n=250)...
November 23, 2016: Clinical Biochemistry
https://www.readbyqxmd.com/read/27888388/cardiac-bin1-cbin1-is-a-regulator-of-cardiac-contractile-function-and-an-emerging-biomarker-of-heart-muscle-health
#7
REVIEW
Kang Zhou, Tingting Hong
In recent decades, a cardiomyocyte membrane scaffolding protein bridging integrator 1 (BIN1) has emerged as a critical multifunctional regulator of transverse-tubule (t-tubule) function and calcium signaling in cardiomyocytes. Encoded by a single gene with 20 exons that are alternatively spliced, more than ten BIN1 protein isoforms are expressed with tissue and disease specificity. The recently discovered cardiac alternatively spliced isoform BIN1 (cBIN1 or BIN1+13+17) plays a crucial role in organizing membrane microfolds within cardiac t-tubules...
November 23, 2016: Science China. Life Sciences
https://www.readbyqxmd.com/read/27878630/diagnostic-and-prognostic-value-of-plasma-levels-of-cardiac-myosin-binding-protein-c-as-a-novel-biomarker-in-heart-failure
#8
Doaa El Amrousy, Hossam Hodeib, Ghada Suliman, Nahed Hablas, Eman Ramadan Salama, Ahmed Esam
Heart failure (HF) has high morbidity and mortality in children. This study aimed to investigate the value of cardiac myosin binding protein-C (cMyBP-C) as a diagnostic and prognostic biomarker in children with heart failure. This study was a prospective case-control study that involved 50 children with acute HF and 25 healthy children of matched age and sex as a control group. cMyBP-C plasma levels were measured in patients with HF at the time of admission and 1 month after treatment. Echocardiographic assessment was done for all children...
November 23, 2016: Pediatric Cardiology
https://www.readbyqxmd.com/read/27872995/nt-probnp-as-marker-of-ventricular-dilatation-and-pulmonary-regurgitation-after-surgical-correction-of-tetralogy-of-fallot-a-mri-validation-study
#9
Annalisa Paolino, Tarique Hussain, Antonio Pavon, Maria Nieves Velasco, Sergio Uribe, Antonio Ordoñez, Israel Valverde
The goal of this study is to evaluate whether NT-proBNP plasma levels may help as a screening biomarker for monitoring right ventricular dilatation, pulmonary regurgitation and the onset of heart failure in patients with repaired Tetralogy of Fallot. Our single-centre observational prospective study involved 43 patients (15.1 years, SD = 8) with corrected Tetralogy of Fallot. Data collection included: clinical parameters (electrocardiogram, chest X-ray, NYHA scale, time since last surgery), biochemistry (NT-proBNP levels) and MRI values (ventricular volumetry, pulmonary flow assessment)...
November 21, 2016: Pediatric Cardiology
https://www.readbyqxmd.com/read/27872884/data-on-clinical-characteristics-of-a-heart-failure-patients-cohort-with-reduced-ejection-fraction-and-analysis-of-the-circulating-values-of-five-different-heart-failure-biomarkers-high-sensitivity-troponin-t-galectin-3-c-terminal-propeptide-of-type-i-procollagen
#10
M Batlle, B Campos, M Farrero, M Cardona, B González, M A Castel, J Ortiz, E Roig, M J Pulgarín, J Ramírez, J L Bedini, M Sabaté, P García de Frutos, F Pérez-Villa
In this article, the full description of a heart failure with reduced ejection fraction (HF_REF) cohort of 192 patients is provided. Tables with the baseline demographic, prior history, ECG parameters, echocardiographic parameters, laboratory values and pharmacological treatment of these patients are included. Also, the quartile values of the analyzed circulating biomarkers: high sensitivity Troponin T (hs-TnT), galectin-3 (Gal-3), C-terminal propeptide of type I procollagen (CICP), soluble AXL (sAXL) and Brain Natriuretic Peptide (BNP) are given...
December 2016: Data in Brief
https://www.readbyqxmd.com/read/27869886/-anmco-elas-sibioc-consensus-document-recommendations-for-the-use-of-cardiac-biomarkers-in-heart-failure-patients
#11
Nadia Aspromonte, Michele Massimo Gulizia, Aldo Clerico, Giuseppe Di Tano, Michele Emdin, Mauro Feola, Massimo Iacoviello, Roberto Latini, Andrea Mortara, Roberto Valle, Gianfranco Misuraca, Claudio Passino, Serge Masson, Alberto Aimo, Marcello Ciaccio, Marco Migliardi
Biomarkers have dramatically impacted the way heart failure (HF) patients are evaluated and managed. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological or pathogenic processes, or pharmacological responses to a therapeutic intervention. Natriuretic peptides (B-type natriuretic peptide [BNP] and N-terminal proBNP) are the gold standard biomarkers in determining the diagnosis and prognosis of HF, and a natriuretic peptide-guided HF management looks promising...
September 2016: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/27861330/increased-mean-aliphatic-lipid-chain-length-in-left-ventricular-hypertrophy-secondary-to-arterial-hypertension-a-cross-sectional-study
#12
Maria Francesca Evaristi, Céline Caubère, Romain Harmancey, Franck Desmoulin, William Frank Peacock, Matthieu Berry, Annie Turkieh, Manon Barutaut, Michel Galinier, Camille Dambrin, Carlo Polidori, Cristina Miceli, Bernard Chamontin, François Koukoui, Jerôme Roncalli, Pierre Massabuau, Fatima Smih, Philippe Rouet
About 77.9 million (1 in 4) American adults have high blood pressure. High blood pressure is the primary cause of left ventricular hypertrophy (LVH), which represents a strong predictor of future heart failure and cardiovascular mortality. Previous studies have shown an altered metabolic profile in hypertensive patients with LVH. The goal of this study was to identify blood metabolomic LVH biomarkers by H NMR to provide novel diagnostic tools for rapid LVH detection in populations of hypertensive individuals...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27856208/randomized-comparison-of-allogeneic-vs-autologous-mesenchymal-stem-cells-for-non-lschemic-dilated-cardiomyopathy-poseidon-dcm-trial
#13
Joshua M Hare, Darcy L DiFede, Angela M Castellanos, Victoria Florea, Ana M Landin, Jill El-Khorazaty, Aisha Khan, Muzammil Mushtaq, Maureen H Lowery, John J Byrnes, Robert C Hendel, Mauricio G Cohen, Carlos E Alfonso, Krystalenia Valasaki, Marietsy V Pujol, Samuel Golpanian, Eduard Ghersin, Joel E Fishman, Pradip Pattany, Samirah A Gomes, Cindy Delgado, Roberto Miki, Fouad Abuzeid, Mayra Vidro-Casiano, Courtney Premer, Audrey Medina, Valeria Porras, Konstantinos E Hatzistergos, Erica Anderson, Adam Mendizabal, Raul Mitrani, Alan W Heldman
BACKGROUND: While human mesenchymal stem cells (hMSCs) have been tested in ischemic cardiomyopathy, few studies exist in chronic non-ischemic dilated cardiomyopathy (NIDCM). OBJECTIVES: The POSEIDON-DCM trial is a randomized comparison of safety and efficacy of autologous (auto) vs. allogeneic (allo) bone marrow-derived hMSCs in NIDCM. METHODS: Thirty-seven patients were randomized to either allo- or auto-hMSCs in a 1:1 ratio. Patients were recruited between December 2011 and July 2015 at the University of Miami Hospital...
November 14, 2016: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/27855182/a-non-human-primate-model-of-severe-pneumococcal-pneumonia
#14
Luis F Reyes, Marcos I Restrepo, Cecilia A Hinojosa, Nilam J Soni, Anukul T Shenoy, Ryan P Gilley, Norberto Gonzalez-Juarbe, Julio R Noda, Vicki T Winter, Melissa A de la Garza, Robert E Shade, Jacqueline J Coalson, Luis D Giavedoni, Antonio Anzueto, Carlos J Orihuela
RATIONALE: Streptococcus pneumoniae is the leading cause of community-acquired pneumonia and infectious death in adults worldwide. A non-human primate model is needed to study the molecular mechanisms that underlie the development of severe pneumonia, identify diagnostic tools, explore potential therapeutic targets, and test clinical interventions during pneumococcal pneumonia. OBJECTIVE: To develop a non-human primate model of pneumococcal pneumonia. METHODS: Seven adult baboons (Papio cynocephalus) were surgically tethered to a continuous monitoring system that recorded heart rate, temperature, and electrocardiography...
2016: PloS One
https://www.readbyqxmd.com/read/27851604/1970-acute-kidney-injury-cell-cycle-arrest-biomarkers-in-acute-on-chronic-heart-failure-a-case-report
#15
Savneek Chugh, Sohaib Tariq
No abstract text is available yet for this article.
December 2016: Critical Care Medicine
https://www.readbyqxmd.com/read/27837155/monocyte-count-hdl-cholesterol-ratio-and-cardiovascular-disease-in-patients-with-obstructive-sleep-apnea-syndrome-a-multicenter-study
#16
Handan Inonu Koseoglu, Ahmet Cemal Pazarli, Asiye Kanbay, Osman Demir
BACKGROUND: Obstructive sleep apnea syndrome (OSAS) is an independent risk factor for cardiovascular disease (CVD). Although monocyte to high-density lipoprotein cholesterol ratio (MHR) is increasingly being implicated in cardiovascular morbidity and mortality, no study has attempted to determine the role of MHR in cardiovascular morbidity of patients with OSAS. We aimed to investigate the association between MHR and CVD in patients with OSAS and the relationship between severity of OSAS, polysomnographic parameters, and MHR...
November 11, 2016: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/27832613/prognostic-value-of-n-terminal-pro-b-type-natriuretic-peptide-troponin-t-and-growth-differentiation-factor-15-in-adult-congenital-heart-disease
#17
Vivan J Baggen, Annemien van den Bosch, Jannet A Eindhoven, Anne-Rose Schut, Judith A A E Cuypers, Maarten Witsenburg, Monique de Waart, Ron H van Schaik, Felix Zijlstra, Eric Boersma, Jolien W Roos-Hesselink
BACKGROUND: -The number of patients with adult congenital heart disease (ACHD) is rapidly increasing. In order to optimize patient management, there is a great need to accurately identify high-risk patients. Still, no biomarker has been firmly established as a clinically useful prognostic tool in this group. We studied the association of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitive troponin-T (hs-TnT) and growth-differentiation factor 15 (GDF-15) with cardiovascular events in ACHD...
November 3, 2016: Circulation
https://www.readbyqxmd.com/read/27825157/biomarkers-in-heart-failure-with-preserved-ejection-fraction-problems-and-opportunities
#18
Filippos K Triposkiadis
No abstract text is available yet for this article.
November 9, 2016: Cardiology
https://www.readbyqxmd.com/read/27823960/searching-for-a-bnp-standard-glycosylated-probnp-as-a-common-calibrator-enables-improved-comparability-of-commercial-bnp-immunoassays
#19
Alexander G Semenov, Natalia N Tamm, Fred S Apple, Karen M Schulz, Sara A Love, Ranka Ler, Evgenia E Feygina, Alexey G Katrukha
BACKGROUND: Circulating B-type natriuretic peptide (BNP) is widely accepted as a diagnostic and risk assessment biomarker of cardiac function. Studies suggest that there are significant differences in measured concentrations among different commercial BNP immunoassays. The purpose of our study was to compare BNP-related proteins to determine a form that could be used as a common calibrator to improve the comparability of commercial BNP immunoassay results. METHODS: BNP was measured in 40 EDTA-plasma samples from acute and chronic heart failure patients using five commercial BNP assays: Alere Triage, Siemens Centaur XP, Abbott I-STAT, Beckman Access2 and ET Healthcare Pylon...
November 4, 2016: Clinical Biochemistry
https://www.readbyqxmd.com/read/27821419/long-noncoding-rnas-in-cardiovascular-pathology-diagnosis-and-therapy
#20
Christian Bär, Shambhabi Chatterjee, Thomas Thum
Vast parts of mammalian genomes encode for transcripts that are not further translated into proteins. The purpose of the majority of such noncoding ribonucleic acids (RNAs) remained paradoxical for a long time. However, a growing body of evidence demonstrates that long noncoding RNAs are dynamically expressed in different cell types, diseases, or developmental stages to execute a wide variety of regulatory roles at virtually every step of gene expression and translation. Indeed, long noncoding RNAs influence gene expression via epigenetic modulations, through regulating alternative splicing, or by acting as molecular sponges...
November 8, 2016: Circulation
keyword
keyword
75967
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"